FDA Approves Free Gene Therapy for Rare Hearing Loss in Children
The Food and Drug Administration (FDA) has approved Otarmeni, a groundbreaking gene therapy for a rare form of inherited hearing loss. Developed by Regeneron, Otarmeni targets OTOF-related deafness, a condition affecting about 50 babies born in the U.S. each year. This therapy delivers a working copy of the OTOF gene directly into the inner ear, restoring the production of otoferlin, a protein essential for hearing. The treatment, administered as a single injection into the cochlea, has shown promising results in clinical trials, with many participants experiencing significant hearing improvements. Notably, Regeneron has announced that the therapy will be provided free of charge to U.S. patients, highlighting the company's commitment to accessibility. 
